Article

Multiple Treatment Interruptions and Protecting HIV-Specific CD4 T-Cells Enables Durable CTL Response and Viral Control

2023-10-25

Abstract excerpt

<h4>ABSTRACT</h4> <h4>BACKGROUND</h4> The cell and gene therapy product AGT103-T was evaluated ( NCT04561258 ) for safety, immunogenicity, and persistence for up to 180 days post infusion. We sought to investigate the impact following analytical treatment interruptions (ATIs). <h4>METHODS</h4> Six patients suspended their antiretroviral therapy (ART) until their viral load reached 100,000 copies/mL in two successi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4351efa5-1f53-5bdc-8f35-8b9e943b110c
DOI: 10.1101/2023.10.24.23297421

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Multiple Treatment Interruptions and Protecting HIV-Specific CD4 T-Cells Enables Durable CTL Response and Viral ControlDOI 10.1101/2023.10.24.23297421Read

Multiple treatment interruptions and protecting HIV-specific CD4 T cells enable durable CD8 T cell response and viral controlSemantic proximity Read

HIV-specific CD8+ T cells and HIV eradicationSemantic proximity Read

Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 InfectionSemantic proximity Read

Prolonged non-suppressible viremia sustained by a clonally expanded, genomically defective provirus with an immune-evasive HIV protein expression profileSemantic proximity Read

Precision Elimination: Proof-of-Concept In Silico Testing of a Novel Construct for Optimizing HIV-1 EradicationSemantic proximity Read

Diverse Impacts of HIV Latency-Reversing Agents on CD8+ T-Cell Function: Implications for HIV CureSemantic proximity Read

Transient Plasma Viral Rebound After Sars-cov-2 Vaccination in an Exceptional Hiv-1 Elite Controller WomanSemantic proximity Read

T cell immunity predicts clinical outcomes on stopping antiretroviral treatment after HIV-specific broadly neutralising antibody therapySemantic proximity Read

HIV-1 persistence during ARTSemantic proximity Read

Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteersSemantic proximity Read

The Current Status of Latency Reversing Agents for HIV-1 RemissionSemantic proximity Read

Broadly neutralizing antibody–derived CAR T cells reduce viral reservoir in individuals infected with HIV-1Semantic proximity Read